<DOC>
	<DOCNO>NCT00658463</DOCNO>
	<brief_summary>Statins show reduce significantly risk cardiovascular event patient type 2 diabetes statin therapy largely recommended high cardiovascular risk population . However , residual cardiovascular risk observe patient type 2 diabetes treat statin . This may due fact statin correct lipid abnormality associate diabetic dyslipidaemia , hyperTG low HDL-cholesterol . Rosuvastatin statin , addition efficacy reduce LDL-cholesterol , show decrease significantly plasma triglyceride . However , effect rosuvastatin triglyceride rich lipoprotein HDL remain unknown . The purpose study analyze effect rosuvastatin 20 mg metabolism triglyceride rich lipoprotein HDL patient Type 2 diabetes use vivo kinetic study VLDL1-apoB , VLDL2-apoB , IDL-apoB HDL-apoA1 .</brief_summary>
	<brief_title>Effects Rosuvastatin , Vivo , Kinetic apoB apoA1 , Using Stable Isotopes , Type 2 Diabetic Patients</brief_title>
	<detailed_description>This randomize , double blind , placebo-controlled , monocentric , cross-over study two 6-week period placebo rosuvastatin . Subjects enter one month placebo lead-in period eligible rosuvastatin 20 mg placebo two 6-week period . An vivo kinetic study perform stable isotope ( 13C leucine ) type 2 diabetic patient ( n=8 ) 6-week period rosuvastatin ( 20mg ) therapy . The study design one-month steady state period placebo cross-over design two 6-week period placebo rosuvastatin ( 20 mg. An vivo kinetic study perform end 6-week period . The kinetic study perform , patient , assess production rate fractional rate VLDL1-apoB , VLDL2-apoB , IDL-apoB , LDL-apoB HDL-apoA-I .</detailed_description>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Provision write informed consent Type 2 diabetic patient ( age : 30 75 year ) treat one two oral agent fix dose ( sulfonylurea , metformin , alpha glucosidase inhibitor ) least 6 month Fasting triglyceride &gt; = 150 mg/dl HDLC &lt; 40 mg/dl men &lt; 50 mg/dl woman ( NCEP ATPIII lipid criterion metabolic syndrome ) Patients receive hypolipidemic agent since least 6 month Diabetic patient stable HbA1c last 6 month Subjects willing follow study procedure include attendance clinic schedule study visit compliance study treatment regimen HbA1c &gt; 9 % LDLC &gt; 190 mg/dl Known heterozygous homozygous familial hypercholesterolaemia know type III hyperlipoproteinaemia ( familial dysbetalipoproteinaemia Documented secondary hypercholesterolaemia cause History serious adverse effect hypersensitivity reaction HMGCoA reductase inhibitor , particular history myopathy Pregnant woman , woman breast feeding woman childbearing potential use chemical mechanical contraception ( prescription oral contraceptive , abstinence , condom spermicide , surgical sterilisation , diaphragm spermicide intrauterine device ) positive pregnancy test History malignancy , except subject disease free 10 year whose malignancy basal squamous cell skin carcinoma . Women history cervical dysplasia exclude unless 3 consecutive normal cervical smear subsequently record entry study History alcohol and/or drug abuse Active liver disease hepatic dysfunction define elevation AST ALT * 2 time ULN . In case , second determination hepatic test perform one week . If dysfunction confirm , subject must include study Patient acromegaly Cushing syndrome Patient receive insulin treatment Use drug know affect lipid metabolism : corticoid , retinoids , antiproteases , estrogen , cyclosporin , glitazones , statin rosuvastatin , fibrates , cholestyramine , nicotinic acid , omega 3 phytosterols Renal impairment define creatinine clearance &lt; 30 ml/min . Unstable angina manifestation severe atherosclerosis . Uncontrolled hypertension define either rest diastolic blood pressure &gt; 95mmHg rest systolic blood pressure &gt; 200 mmHg . Unexplained serum CK &gt; 3 time ULN ( eg . due recent trauma , intramuscular injection , heavy exercise , etc ) . Participation another investigational drug trial within 4 week prior randomization . Subjects serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation trial . Subjects serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Triglycerides</keyword>
	<keyword>HDL-cholesterol</keyword>
	<keyword>kinetic</keyword>
	<keyword>rosuvastatin</keyword>
</DOC>